All In Biotech

Drug Trial Radar · NCT00000479

Women's Health Study (WHS): A Randomized Trial of Low-dose Aspirin and Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer

Women's Health Study of Low-dose Aspirin and Vitamin E in Apparently Healthy Women

Last checked: Nov 20, 2026Latest source record: Jun 15, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 39,876 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

39,876

Actual

Start

Sep 1992

Primary completion

Mar 2004

Study completion Feb 2005

Sponsor

Lead sponsor
Brigham and Women's HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute (NHLBI)
First posted
Oct 28, 1999

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
Female only, from 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effects of low-dose aspirin and vitamin E in primary prevention of cardiovascular disease and cancer in apparently healthy women.

Conditions

  • Cardiovascular Diseases
  • Cerebrovascular Disorders
  • Coronary Disease
  • Heart Diseases
  • Myocardial Infarction
  • Myocardial Ischemia
  • Vascular Diseases

Interventions

  • AspirinDrug

    Participants will receive 100 mg of aspirin every other day.

  • Vitamin EDrug

    Participants will receive 600 IU of vitamin E every other day.

  • PlaceboBehavioral

    Participants will receive placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Major Cardiovascular Events (a Combined Endpoint of Nonfatal Myocardial Infarction, Nonfatal Stroke, and Total Cardiovascular Death)Time frame: Average follow-up 10.1 years
  2. Number of Participants With Cancer, Excluding Nonmelanoma Skin CancerTime frame: Average follow-up 10.1 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.